Literature DB >> 28555670

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.

Nisha Nagarsheth1,2, Max S Wicha2,3,4, Weiping Zou1,2,4.   

Abstract

The tumour microenvironment is the primary location in which tumour cells and the host immune system interact. Different immune cell subsets are recruited into the tumour microenvironment via interactions between chemokines and chemokine receptors, and these populations have distinct effects on tumour progression and therapeutic outcomes. In this Review, we focus on the main chemokines that are found in the human tumour microenvironment; we elaborate on their patterns of expression, their regulation and their roles in immune cell recruitment and in cancer and stromal cell biology, and we consider how they affect cancer immunity and tumorigenesis. We also discuss the potential of targeting chemokine networks, in combination with other immunotherapies, for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28555670      PMCID: PMC5731833          DOI: 10.1038/nri.2017.49

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  212 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.

Authors:  Romaine I Fernando; Marianne D Castillo; Mary Litzinger; Duane H Hamilton; Claudia Palena
Journal:  Cancer Res       Date:  2011-06-08       Impact factor: 12.701

3.  Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.

Authors:  Galina V Shurin; Robert L Ferris; Robert Ferris; Irina L Tourkova; Lori Perez; Anna Lokshin; Levent Balkir; Bobby Collins; Gurkamal S Chatta; Michael R Shurin
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

4.  CCL18 promotes epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma.

Authors:  Fanbin Meng; Wan Li; Changling Li; Zhigang Gao; Kejian Guo; Shaowei Song
Journal:  Int J Oncol       Date:  2014-12-10       Impact factor: 5.650

5.  Expression of CXCL14 and its anticancer role in breast cancer.

Authors:  Xiao-Li Gu; Zhou-Luo Ou; Feng-Juan Lin; Xiao-Li Yang; Jian-Min Luo; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  Breast Cancer Res Treat       Date:  2012-08-22       Impact factor: 4.872

6.  Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43.

Authors:  Kendle M Maslowski; Angelica T Vieira; Aylwin Ng; Jan Kranich; Frederic Sierro; Di Yu; Heidi C Schilter; Michael S Rolph; Fabienne Mackay; David Artis; Ramnik J Xavier; Mauro M Teixeira; Charles R Mackay
Journal:  Nature       Date:  2009-10-29       Impact factor: 49.962

7.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Authors:  Marie Vétizou; Jonathan M Pitt; Romain Daillère; Patricia Lepage; Nadine Waldschmitt; Caroline Flament; Sylvie Rusakiewicz; Bertrand Routy; Maria P Roberti; Connie P M Duong; Vichnou Poirier-Colame; Antoine Roux; Sonia Becharef; Silvia Formenti; Encouse Golden; Sascha Cording; Gerard Eberl; Andreas Schlitzer; Florent Ginhoux; Sridhar Mani; Takahiro Yamazaki; Nicolas Jacquelot; David P Enot; Marion Bérard; Jérôme Nigou; Paule Opolon; Alexander Eggermont; Paul-Louis Woerther; Elisabeth Chachaty; Nathalie Chaput; Caroline Robert; Christina Mateus; Guido Kroemer; Didier Raoult; Ivo Gomperts Boneca; Franck Carbonnel; Mathias Chamaillard; Laurence Zitvogel
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration.

Authors:  Caterina Ierano; Paola Giuliano; Crescenzo D'Alterio; Michele Cioffi; Valentina Mettivier; Luigi Portella; Maria Napolitano; Antonio Barbieri; Claudio Arra; Giuseppina Liguori; Renato Franco; Giuseppe Palmieri; Carla Rozzo; Roberto Pacelli; Giuseppe Castello; Stefania Scala
Journal:  Cell Cycle       Date:  2009-04-23       Impact factor: 4.534

10.  Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.

Authors:  A Q Sukkurwala; I Martins; Y Wang; F Schlemmer; C Ruckenstuhl; M Durchschlag; M Michaud; L Senovilla; A Sistigu; Y Ma; E Vacchelli; E Sulpice; X Gidrol; L Zitvogel; F Madeo; L Galluzzi; O Kepp; G Kroemer
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

View more
  568 in total

1.  Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer.

Authors:  Zheng Liu; Yu Zhu; Le Xu; Junyu Zhang; Huyang Xie; Hangcheng Fu; Quan Zhou; Yuan Chang; Bo Dai; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

2.  Chemokine-like factor 1: A promising therapeutic target in human diseases.

Authors:  Xiaopeng Cai; Jingwen Deng; Qianqian Ming; Huiqiang Cai; Zhi Chen
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-26

3.  Identification of the dominant angiogenic CXCL class chemokines associated with non-small cell lung cancer via bioinformatics tools.

Authors:  Nese Unver
Journal:  Med Oncol       Date:  2021-05-13       Impact factor: 3.064

Review 4.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

Review 5.  Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

Authors:  Victoria Wu; Huwate Yeerna; Nijiro Nohata; Joshua Chiou; Olivier Harismendy; Francesco Raimondi; Asuka Inoue; Robert B Russell; Pablo Tamayo; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

6.  Schistosoma mansoni PCR+ -infected individuals in the Sudan present elevated systemic levels of chemokines when compared to uninfected and egg+ cohorts.

Authors:  K Arndts; T E M Elfaki; N Jelden; M Ritter; A Wiszniewsky; G Katawa; I A Goreish; M E Y A Atti El Mekki; M J Doenhoff; A Hoerauf; L E Layland
Journal:  Clin Exp Immunol       Date:  2019-03-19       Impact factor: 4.330

7.  Epigenetic regulation of miR-518a-5p-CCR6 feedback loop promotes both proliferation and invasion in diffuse large B cell lymphoma.

Authors:  Qian Huang; Feng Zhang; Haiying Fu; Jianzhen Shen
Journal:  Epigenetics       Date:  2020-06-30       Impact factor: 4.528

Review 8.  Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.

Authors:  M Segovia; S Russo; M R Girotti; G A Rabinovich; M Hill
Journal:  Clin Exp Immunol       Date:  2020-05       Impact factor: 4.330

Review 9.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Authors:  Dingxiao Zhang; Dean G Tang; Kiera Rycaj
Journal:  Semin Cancer Biol       Date:  2018-05-09       Impact factor: 15.707

10.  IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors.

Authors:  Sahil Gupta; Arpit Jain; Shahzad Nawaz Syed; Ryan G Snodgrass; Beatrice Pflüger-Müller; Matthias S Leisegang; Andreas Weigert; Ralf P Brandes; Ingo Ebersberger; Bernhard Brüne; Dmitry Namgaladze
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.